Search for: "State v. Tri-State Pharmaceutical"
Results 61 - 80
of 455
Sort by Relevance
|
Sort by Date
1 Nov 2020, 12:57 pm
The memo identifies a number of trends with respect to the COVID-19-related securities litigation so far: first, the pharmaceuticals industry has been the “biggest area of focus” for the plaintiffs’ lawyers so far, as six pharmaceutical companies have been named as defendants in coronavirus-related securities lawsuits. [read post]
10 Aug 2020, 9:38 am
” Here is the two-part definition: The Critical Inputs, which includes the active pharmaceutical ingredients (API), used to produce the “Essential Medicines” or “Medical Countermeasures” must be produced in the United States; and The finished drug or device must be manufactured, prepared, propagated, compounded, or processed in the United States. [read post]
3 Aug 2020, 6:56 am
Another empirical test of Beshada’s fairness occurred in a state court case tried before the Hon. [read post]
26 Jun 2020, 2:53 am
On the ball as always, Joost told me that the appeal in Neurim Pharmaceuticals v. [read post]
25 Jun 2020, 3:49 am
A copy of the appeal judgment can be found here. [1] We use the Neurim to refer to Neurim and its exclusive licensee, Flynn, unless otherwise stated. [read post]
14 Jun 2020, 9:14 am
These observations are based on the Delaware Supreme Court’s 2019 decision in Marchand v. [read post]
11 Jun 2020, 11:30 pm
Madigan tried to avoid that result here [of having two statistically non-significant results] by conducting a ‘meta-analysis’ — a greywashed term meaning that he combined two statistically insignificant results to try to achieve statistical significance. [read post]
10 Jun 2020, 8:10 am
Interestingly, the Judge also stated that there are means other than an application for summary judgment for showing that there is no serious issue to be tried. [read post]
5 Jun 2020, 3:00 am
Campaign Funds for Judges Warp Criminal Justice, Study Finds New York Times – Adam Liptak | Published: 6/1/2020 In Gideon v. [read post]
2 Jun 2020, 10:35 am
Federal and State Prosecutions against Physicians and Screening Companies After Judge Jack’s exposé of fraudulent and false diagnoses in the silicosis MDL, various news media reported that the United States Attorney’s office in the Southern District of New York was investigating possible criminal charges against the physicians and lawyers who orchestrated the screenings. [read post]
21 Apr 2020, 6:30 am
In Valeant Pharmaceuticals International, Inc. v. [read post]
28 Mar 2020, 1:38 pm
The recent Court of International Trade case TR International Trading Company v. [read post]
13 Mar 2020, 1:53 am
It can therefore serve as a form of prototype for other Member States, while also having its own characteristics such as a lack of a domestic pharmaceutical manufacturing industry and the effects of the single point of entry to a reimbursement system.Rochelle C. [read post]
12 Mar 2020, 1:48 am
In line with Lord Justice Jacob’s point in Actavis v Merck, the Court of Appeal stated that – in certain circumstances – there is nothing inventive about routinely-taken steps even if the actual outcome had not been predicted. [read post]
9 Oct 2019, 3:23 pm
Notably, CMS and OIG propose to expressly exclude, or are seeking comments regarding whether to exclude, certain entities from participating in protected arrangements on the basis of historical enforcement and oversight experience: (i) pharmaceutical manufacturers; (ii) manufacturers, distributors, or suppliers of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS); (iii) laboratories; (iv) pharmacy benefit managers; and (v) other wholesalers and distributors. [read post]
4 Oct 2019, 4:38 pm
Courts of Appeal after Blakely v. [read post]
27 Sep 2019, 6:00 am
Trying to nullify state capture. [read post]
14 Aug 2019, 7:25 am
Ethicon Ltd [1975] AC 396. [2] Campus Oil v Minister for Industry [1983] IR 38. [3] Okunade v. [read post]
7 Aug 2019, 1:47 pm
In Colon v. [read post]
27 Jun 2019, 6:33 am
The case concerned two giants of the bio-pharmaceuticals world, Roche and Pfizer, and Roche's blockbuster biologic, Avastin. [read post]
